Leo Pharma has appointed GlaxoSmithKline’s (GSK) Dr Sathish Kolli as medical director for the UK and Ireland.
Dr Kolli was acting global medical affairs director, Neuroscience Centre of Excellence at GSK having previously served as the company’s medical director from 2010 to 2012.
Prior to this, he was head of compliance at AstraZeneca and he has further compliance experience e at Schwarz.
Dr Kolli explained that his move to a smaller company was influenced by Leo Pharma’s more patient-centred approach to life sciences.
“LEO are not just talking about putting the patient first, they are actually living this value with their ‘total care solutions’, patient support programmes and joint working projects in the UK,” he said.
“I have always felt pharma companies can be doing more than just supplying medicines and by leading the medical team, in the medical director role, I look forward to helping the company continue to drive this patient centred approach”.
Geraldine Murphy, managing director, LEO Pharma UK/Ireland, said: “I am confident that his leadership, together with extensive clinical knowledge and pharmaceutical expertise, gained across several different therapy areas will prove to be invaluable to our dermatology and thrombosis teams and help us in our quest to deliver improved outcomes to patients.”